PharmaShots | Incisive News in 3 Shots

Subscribe Now

wet amd

Regenxbio Presented Interim Results of RGX-314 in P-II AAVIATE and ALTITUDE Trials for Wet AMD and Diabetic Retinopathy at AAO 2021

Regenxbio Presented Interim Results of RGX-314 in P-II AAVIATE and ALTITUDE Trials for Wet AMD and Diabetic Retinopathy at AAO 202...

November 15, 2021

Outlook Reports Results of ONS-5010 / Lytenava (bevacizumab-vikg) in P-III NORSE TWO Trial for the Treatment of Wet AMD

Outlook Reports Results of ONS-5010 / Lytenava (bevacizumab-vikg) in P-III NORSE TWO Trial for the Treatment of Wet AMD

August 4, 2021

Regenxbio Reports the Initiation of First Pivotal Program for RGX-314 to Treat Wet AMD

Regenxbio Reports the Initiation of First Pivotal Program for RGX-314 to Treat Wet AMD

January 6, 2021

Novartis' Beovu (brolucizumab) Receives EMA's Approval for its Safety Label Update to Treat Wet Age-Related Macular Degeneration

Novartis' Beovu (brolucizumab) Receives EMA's Approval for its Safety Label Update to Treat Wet Age-Related Macular Degeneration

September 15, 2020

Regenxbio Reports First Patients Dosing in its P-II AAVIATE Study of RGX-314 for Wet AMD

Regenxbio Reports First Patients Dosing in its P-II AAVIATE Study of RGX-314 for Wet AMD

September 9, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us